PT-141 for Women: How the FDA-Approved Peptide Works for Sexual Health and Libido

For many women, the conversation about low sexual desire starts and ends with a vague acknowledgment that something has changed, followed by a list of lifestyle suggestions and not much else. Sleep better. Reduce stress. Exercise more. Spend quality time with your partner. All reasonable advice, and none of it gets at what is actually happening biologically when desire simply stops showing up the way it used to.

What a significant portion of women experiencing this shift are dealing with is a recognized medical condition called hypoactive sexual desire disorder, or HSDD. It is characterized by persistently low or absent desire for sexual activity that causes real distress, and it is not explained by relationship problems, depression, medication side effects, or any other identifiable cause. It affects premenopausal and postmenopausal women, and it is far more common than the silence around it suggests.

PT-141, known generically as bremelanotide and marketed under the brand name Vyleesi, is the only FDA-approved on-demand peptide treatment specifically studied for HSDD in women. It works through an entirely different mechanism than anything else in the sexual health space, and understanding how it works is the starting point for understanding whether it is even a relevant conversation to have with a licensed provider. This guide covers the mechanism, the clinical evidence, the practical picture, and what the honest questions are before any such conversation begins.

For broader context on how peptide therapy works as a category, the Complete Beginner’s Guide to Peptide Therapy provides a useful foundation. For women also exploring hormonal considerations, the article on Menopause and Hormones: What Women Over 45 Need to Know covers the hormonal landscape in depth.

What Is HSDD and Why Does It Matter

Hypoactive sexual desire disorder is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The key word is distress. Not every woman who experiences a change in desire has HSDD. The clinical distinction is that the change causes genuine, ongoing distress to the woman herself, regardless of how her partner feels about it.

HSDD is classified as either acquired (developed after a period of normal desire) or lifelong (present throughout a woman’s sexual history), and as either generalized (occurring in all situations) or situational (occurring only in specific contexts). The FDA-approved indication for bremelanotide covers acquired, generalized HSDD in premenopausal women, which is also the population studied in the pivotal clinical trials.

The condition is more prevalent than most people realize. Studies have estimated that between 8 and 10% of premenopausal women have HSDD with associated distress, and the numbers increase significantly in the perimenopausal and postmenopausal population. Despite this prevalence, treatment options have historically been extremely limited. Flibanserin (Addyi), approved in 2015, is the only other FDA-approved treatment and requires daily oral dosing with significant dietary and alcohol restrictions. PT-141 is administered on demand, as needed before anticipated sexual activity, which is a fundamentally different approach.

How PT-141 Works: The Brain, Not the Body

Understanding PT-141 requires understanding what most sexual health treatments target compared to what PT-141 targets. PDE5 inhibitors like sildenafil work peripherally, by increasing blood flow to genital tissue in response to arousal that is already present. They do not generate desire. They facilitate the physical response to desire that is already occurring. For women with HSDD, there is no arousal present to respond to, which is why these medications are largely irrelevant to the condition.

PT-141 works upstream. It is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) that acts as a selective agonist at melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) in the hypothalamus and limbic system. When MC4 receptors are activated in the medial preoptic area of the hypothalamus, dopamine is released into reward and motivation circuits, including the nucleus accumbens. This is the neurological pathway through which desire itself is initiated.

This central mechanism explains why PT-141 can be effective for women whose issue is the absence of desire rather than a physical barrier to sexual response. It is not treating the symptom downstream. It is activating the pathway where desire originates.

PT-141 was originally developed as a sunless tanning agent from its predecessor Melanotan II, and the sexual desire effects were discovered as an unexpected finding during early clinical trials. That origin is clinically relevant because it reflects a genuine biological mechanism rather than a constructed pharmaceutical effect. The melanocortin system has documented roles in appetite, energy balance, and sexual behavior across multiple species, and the human data from bremelanotide trials represents the most rigorous clinical validation of that mechanism to date.

The Clinical Evidence: What the RECONNECT Trials Found

The FDA approval of bremelanotide as Vyleesi in June 2019 was based on the RECONNECT trial program, which comprised two randomized, double-blind, placebo-controlled Phase 3 trials enrolling a combined 1,247 premenopausal women with acquired, generalized HSDD. This is the most rigorous evidence base of any peptide in the sexual health category.

A few important points of context around these results. The improvement rate in the PT-141 group (25%) versus placebo (17%) reflects a modest but statistically significant difference. This is not unusual for sexual function trials, where placebo response rates tend to be high because of measurement complexity and the psychological dimensions of sexual desire. The FDA accepted these results as sufficient to support approval because both co-primary endpoints were met in both trials and the effect was consistent across subgroups.

The FSFI effect size of 0.49 to 0.61 is more clinically informative. In sexual function research, effect sizes in the medium range are generally considered meaningful because the outcome being measured, desire, is inherently subjective and resistant to large effect sizes in controlled trials. For reference, many pharmacological treatments in psychiatry are approved with similar effect sizes.

Dosing and Administration: What the FDA Label Specifies

PT-141 (Vyleesi) is administered as a 1.75 mg subcutaneous injection, typically into the abdomen or thigh. The FDA prescribing information specifies the following:

• Inject approximately 45 minutes before anticipated sexual activity
• Maximum one dose in any 24-hour period
• Do not use more than once per day or more than approximately eight times per month on a regular basis
• The drug reaches maximum blood concentration within 30 to 60 minutes
• Effects can last for several hours

Safety Profile: What to Know Before the Conversation

The RECONNECT trials established a safety database from 1,247 participants, providing meaningful real-world signal detection at the Phase 3 level. The safety profile is well characterized for premenopausal women in the approved indication.

Most Common Side Effects

Nausea is the most frequently reported side effect, occurring in approximately 40% of patients on the first dose. In the majority of cases, this is transient and decreases significantly with continued use. Facial flushing and headache are also commonly reported. These effects are related to the melanocortin pathway activation and are generally mild to moderate in severity.

Blood Pressure Consideration

PT-141 can transiently decrease blood pressure. The FDA prescribing information advises that blood pressure should be measured before each injection, and the drug should not be used if the patient’s blood pressure is already low. The prescribing information also recommends waiting at least 12 hours after any cardiovascular medication before using PT-141. Women with uncontrolled hypertension or cardiovascular disease should not use it.

Who Should Not Use PT-141

PT-141 vs Addyi: Two Different Approaches

Addyi (flibanserin), approved in 2015, was the first FDA-approved treatment for HSDD and the first treatment for any female sexual disorder. It works through a different mechanism, modulating serotonin and dopamine via 5-HT1A agonism and 5-HT2A antagonism. Understanding the practical differences between the two helps explain why PT-141 may be a better fit for some women and Addyi for others.

Neither approach is inherently superior. Which option, if either, belongs in a treatment plan is a clinical determination based on the individual’s health history, other medications, lifestyle, and specific symptom presentation. A licensed provider familiar with female sexual dysfunction will consider both, alongside hormonal factors, relationship context, and any contributing psychological dimensions.

PT-141 in the Context of Menopause and Hormonal Decline

One of the most important nuances to understand is what PT-141 does and does not address in the context of menopausal hormonal change. As estrogen and testosterone decline through perimenopause and menopause, the reasons for reduced desire become multifactorial. Vaginal atrophy causes discomfort that makes sex less appealing. Lower estrogen reduces central dopaminergic signaling. Declining testosterone (which falls gradually through the 30s and 40s) affects energy, motivation, and libido through separate mechanisms.

PT-141’s approval is specifically for premenopausal women. In postmenopausal women, its use is considered off-label, meaning it can be prescribed by a licensed physician who determines it is appropriate for an individual patient, but there is no equivalent RCT dataset from a postmenopausal population to draw on. Some providers do discuss PT-141 for postmenopausal women when the central desire pathway is the primary concern, and when genitourinary and hormonal components are being addressed separately.

This is where the intersection with hormone therapy becomes relevant. For postmenopausal women experiencing low desire as part of a broader hormonal picture, addressing estrogen and testosterone through HRT may produce more meaningful improvement in desire than PT-141 alone could. The two approaches are not mutually exclusive, but they target different parts of the same problem. A thorough evaluation is the starting point for understanding which component to address first. The lab evaluation relevant to this conversation is covered in the companion article, What Labs Do You Need Before Starting Peptide Therapy.

What a Realistic Conversation With a Provider Looks Like

Bringing PT-141 into a provider conversation is not the same as requesting a prescription. It is the start of an evaluation. A thorough assessment before any HSDD treatment involves reviewing the onset and duration of the symptom, ruling out contributing psychological, relational, or medication-related causes, evaluating hormonal status (particularly testosterone and estradiol), reviewing cardiovascular history and current blood pressure, discussing other medications that might interact, and establishing whether the symptom meets the criteria for acquired, generalized HSDD.

Not every woman who experiences reduced desire has HSDD, and not every woman with HSDD is an appropriate candidate for PT-141 specifically. The diagnostic picture matters as much as the treatment option. A provider who prescribes PT-141 without a careful evaluation is not practicing appropriate care.

For women exploring this in the context of broader hormone optimization, the PT-141 service page provides additional information on how licensed specialists approach this conversation within a comprehensive protocol.